Replies to post #142378 on Biotech Values

[DewDiligence]

ONXX—One might think that using KRAS patients makes sense given the MOA of Nexavar. Was the omission likely due to the small numbers of such patients alive after two or more treatment?

I’m not sure. One possible reason is that the relevance of KRAS in NSCLC was less established when this study was designed, which was in 2008. (The study began enrolling patients in early 2009.)